EOS imaging, a France-based company specializing in orthopedic 2D/3D imaging, has announced that the FDA has cleared the Micro Dose feature for pediatric imaging.
The company indicates that the initial results presented at the 2013 French Society of Radiology Annual Meeting and during the 2014 Annual Meeting of the Radiological Society of North America concluded that Micro Dose generates dosage levels equivalent to a week of naturally-occurring background radiation in pediatric patients receiving 2D and 3D follow-up examinations.
Marie Meynadier, Ph.D., CEO of EOS imaging, said in the January 26, 2015 news release, “The reduction of radiation exposure during orthopedic imaging exams remains a foremost concern among radiologists, orthopedic surgeons and patients. The Micro Dose solution is a giant step forward and is in full accordance with the ALARA (as low as reasonably achievable) principle. We are pleased that the FDA’s clearance of our Micro Dose feature will now enable young patients to benefit from this technology in the United States.”
Meynadier told OTW, “The long term health and well-being of pediatric patients is a foremost concern for EOS imaging as research indicates that pediatric patients are particularly sensitive to adverse effects associated with cumulative exposure to radiation. This sensitivity makes Micro Dose an important solution for addressing the medical needs of young patients with orthopedic conditions requiring frequent imaging exams, such as scoliosis. FDA clearance of Micro Dose will make this technology available to our U.S. users and will continue to solidify EOS’ leadership position in low-dose, 2D/3D imaging.”
